01:12 PM EDT, 05/16/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Thursday that its investigational long-acting antibody sipavibart showed potential in preventing COVID-19 in immunocompromised patients in a phase 3 trial.

The company said the pre-exposure prophylaxis trial met its primary endpoints of relative risk reduction of symptomatic COVID-19 caused by any SARS-COV-2 variant and relative risk reduction of COVID-19 caused by variants without the F456L mutation.

Sipavibart, formerly known as AZD3152, was also well-tolerated in the trial, with adverse events "balanced" between the control and sipavibart arms, according to AstraZeneca ( AZN ).

The company said it is in dialogue with regulators on a potential approval pathway for the antibody.

Price: 77.20, Change: +0.22, Percent Change: +0.29